Search

Your search keyword '"Naruto, Kensuke"' showing total 34 results
Start Over Author "Naruto, Kensuke"
34 results on '"Naruto, Kensuke"'

1. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

Author

Johira, Yusuke, Nakahara, Takashi, Kinami, Takahiro, Yamasaki, Shintaro, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Hayes, C. Nelson, Tsuge, Masataka, Imamura, Michio, Aikata, Hiroshi, and Oka, Shiro

Published
2023
Full Text
View/download PDF

2. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection

Author

Kodama, Kenichiro, Kawaoka, Tomokazu, Kosaka, Masanari, Johira, Yusuke, Shirane, Yuki, Miura, Ryoichi, Yano, Shigeki, Murakami, Serami, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Miki, Daiki, Imamura, Michio, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, Aikata, Hiroshi, and Chayama, Kazuaki

Published
2022
Full Text
View/download PDF

3. Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Author

Naruto, Kensuke, Kawaoka, Tomokazu, Kodama, Kenichiro, Ogawa, Yutaro, Amioka, Kei, Yoshikawa, Yuki, Kikukawa, Chihiro, Suehiro, Yousuke, Yamaoka, Kenji, Ando, Yuwa, Kosaka, Yumi, Uchikawa, Shinsuke, Nakahara, Takashi, Murakami, Eisuke, Ono, Atsushi, Uchida, Takuro, Yamauchi, Masami, Okamoto, Wataru, Takahashi, Shoichi, Imamura, Michio, Chosa, Keigo, Awai, Kazuo, Kubo, Katsumaro, Nagata, Yasushi, Chayama, Kazuaki, and Aikata, Hiroshi

Published
2022
Full Text
View/download PDF

4. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices

Author

Shirane, Yuki, Murakami, Eisuke, Imamura, Michio, Kosaka, Masanari, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Uchikawa, Shinsuke, Teraoka, Yuji, Uchida, Takuro, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Kawaoka, Tomokazu, Miki, Daiki, Yamauchi, Masami, Okamoto, Wataru, Tsuge, Masataka, Chosa, Keigo, Awai, Kazuo, Aikata, Hiroshi, and Oka, Shiro

Published
2022
Full Text
View/download PDF

5. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma

Author

Kinami, Takahiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2024
Full Text
View/download PDF

7. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.

Author

Kikugawa, Chihiro, Uchikawa, Shinsuke, Kawaoka, Tomokazu, Kinami, Takahiro, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Yamaoka, Kenji, Tsuge, Masataka, Kosaka, Yumi, Ohya, Kazuki, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Kouno, Hirotaka, Kohno, Hiroshi, Morio, Kei, Moriya, Takashi, and Nonaka, Michihiro

Subjects
LIVER physiology, THERAPEUTIC use of antineoplastic agents, COMBINATION drug therapy, PEARSON correlation (Statistics), STATISTICAL significance, BEVACIZUMAB, FISHER exact test, LOGISTIC regression analysis, SORAFENIB, TREATMENT effectiveness, RETROSPECTIVE studies, MANN Whitney U Test, CHI-squared test, MULTIVARIATE analysis, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, LONGITUDINAL method, KAPLAN-Meier estimator, LOG-rank test, LUNG tumors, STATISTICS, CANCER patient psychology, PROGRESSION-free survival, DATA analysis software, HEPATOCELLULAR carcinoma, LIVER function tests, OVERALL survival, PROPORTIONAL hazards models
Abstract

Introduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival. Methods: A total of 825 patients with advanced HCC and Child-Pugh A or B received either Sor, Len or Atezo + Bev as first-line systemic therapy. Liver function was assessed according to the Child-Pugh score and the modified albumin-bilirubin (mALBI) grade. Results: Prognosis was analyzed according to liver function such as Child-Pugh classifications, scores, and mALBI grades that worsened with a decline in liver function (p <0.001 for all). A Child-Pugh score of 7 was a factor significantly associated with OS. In patients with a Child-Pugh score of 7, an mALBI grade of 3 was an independent predictor of OS. In Child-Pugh B patients with HCC, receiving Atezo + Bev was identified as a factor associated with PFS. Conclusion: Determining the hepatic reserve of patients with unresectable HCC might be useful for identifying patents suitable for systemic treatment for HCC. Atezo + Bev might prolong the PFS of patients with a Child-Pugh score of 7. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

Author

Yano, Shigeki, Kawaoka, Tomokazu, Johira, Yusuke, Miura, Ryoichi, Kosaka, Masanari, Shirane, Yuki, Murakami, Serami, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Yamaoka, Kenji, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ohno, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Mori, Keiichi, Arihiro, Kouji, Kuroda, Shintaro, Kobayashi, Tsuyoshi, Ohdan, Hideki, and Aikata, Hiroshi

Published
2021
Full Text
View/download PDF

9. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Author

Yano, Shigeki, primary, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Teraoka, Yuji, additional, Kouno, Hirotaka, additional, Takaki, Shintaro, additional, Mori, Nami, additional, Tsuji, Keiji, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

10. Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab

Author

Kikugawa, Chihiro, primary, Uchikawa, Shinsuke, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Tsuge, Masataka, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yohji, additional, Naeshiro, Noriaki, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

11. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib

Author

Chihiro, Kikukawa, primary, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Teraoka, Yuji, additional, Uchida, Takuro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

12. Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma

Author

Kosaka, Yumi, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Kodama, Kenichiro, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ohno, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, and Aikata, Hiroshi, additional

Published
2023
Full Text
View/download PDF

13. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

Author

Kinami, Takahiro, primary, Amioka, Kei, additional, Kawaoka, Tomokazu, additional, Uchikawa, Shinsuke, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

14. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions

Author

Yano, Shigeki, primary, Kimura, Tomoki, additional, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Hirokawa, Junichi, additional, Nagata, Yasushi, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

15. Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial

Author

Naruto, Kensuke, primary, Kawaoka, Tomokazu, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Ogawa, Yutaro, additional, Yoshikawa, Yuki, additional, Yamaoka, Kenji, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Fujii, Yasutomo, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Miki, Daiki, additional, Tsuge, Masataka, additional, and Oka, Shiro, additional

Published
2023
Full Text
View/download PDF

16. Additional file 1 of Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices

Author

Shirane, Yuki, Murakami, Eisuke, Imamura, Michio, Kosaka, Masanari, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Uchikawa, Shinsuke, Teraoka, Yuji, Uchida, Takuro, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Kawaoka, Tomokazu, Miki, Daiki, Yamauchi, Masami, Okamoto, Wataru, Tsuge, Masataka, Chosa, Keigo, Awai, Kazuo, Aikata, Hiroshi, and Oka, Shiro

Abstract

Additional file 1. Supplementary figure 1. (a) Receiver operating characteristic (ROC) curve of hepatic venous pressure gradient (HVPG) measured after performing balloon-occluded retrograde transvenous obliteration (BRTO) (post-HVPG) and exacerbation of esophageal varices (EVs) after BRTO. (b) ROC curve of liver stiffness measurement (LSM) and prognosis after BRTO.

Published
2023
Full Text
View/download PDF

17. Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Author

Ando, Yuwa, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Johira, Yusuke, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Kodama, Kenichiro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Okamoto, Wataru, additional, Takahashi, Shoichi, additional, Imamura, Michio, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

18. Effect of supplemental branched-chain amino acid-enriched nutrients during endoscopic injection sclerotherapy or endoscopic variceal ligation in patients with liver cirrhosis

Author

Kikugawa, Chihiro, primary, Hiramatsu, Akira, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Johira, Yusuke, additional, Kosaka, Masanari, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Yamaoka, Kenji, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Oono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Kawaoka, Tomokazu, additional, Tsuge, Masataka, additional, Imamura, Michio, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

19. Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Kinami, Takahiro, additional, Yamasaki, Shintaro, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Fujii, Yasutoshi, additional, Uchikawa, Shinsuke, additional, Ono, Atsushi, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Kosaka, Yumi, additional, Ohya, Kazuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hioshi, additional, Morio, Kei, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Nonaka, Michihiro, additional, Aisaka, Yasuyuki, additional, Azakami, Takahiro, additional, Hiramatsu, Akira, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

20. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiff measurement predict the prognosis of the patients with gastric varices

Author

Shirane, Yuki, primary, Murakami, Eisuke, additional, Imamura, Michio, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Uchikawa, Shinsuke, additional, Teraoka, Yuji, additional, Uchida, Takuro, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Kawaoka, Tomokazu, additional, Miki, Daiki, additional, Yamauchi, Masami, additional, Okamoto, Wataru, additional, Tsuge, Masataka, additional, Chosa, Keigo, additional, Awai, Kazuo, additional, Aikata, Hiroshi, additional, and Oka, Shiro, additional

Published
2022
Full Text
View/download PDF

21. Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Author

Ando, Yuwa, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Kosaka, Yumi, Uchikawa, Shinsuke, Kodama, Kenichiro, Fujino, Hatsue, Nakahara, Takashi, Ono, Atushi, Murakami, Eisuke, Yamauchi, Masami, Okamoto, Wataru, and Takahashi, Shoichi

Subjects
ATEZOLIZUMAB, PROTEINURIA, BEVACIZUMAB, SYSTOLIC blood pressure, SERUM albumin
Abstract

Introduction: Proteinuria is one of the adverse events of atezolizumab plus bevacizumab combination therapy (Atezo + Bev) and can cause interruption in the use of Bev. However, the risk factors for proteinuria in patients with hepatocellular carcinoma (HCC) who are receiving Atezo + Bev have not yet been investigated. The aim of this study was to identify the risk factors for early onset of proteinuria in Atezo + Bev for patients with unresectable HCC. Methods: Sixty-four patients with Child-Pugh scores of 5–7, an Eastern Cooperative Oncology Group performance status of 0 or 1, and low level of proteinuria (1+ or less on a dipstick test and urine protein-to-creatinine ratio (UPCR) less than 2.0 g/g Cr) at the initiation of therapy were analyzed. The level of proteinuria was evaluated based on the Common Terminology Criteria for Adverse Events version 5.0. We adopted the UPCR for the quantitative test instead of a 24-h urine collection. The incidence of proteinuria and changes in liver function were retrospectively investigated. Results: The cumulative incidence of proteinuria over a 24-week period was 34.4%. Multivariate analysis showed that a low estimated glomerular filtration rate (hazard ratio [HR], 3.807; 95% confidence interval [CI], 1.579–9.180; p = 0.003), treatment for hypertension (HR, 6.224; 95% CI, 1.614–24.010; p = 0.008), and high systolic blood pressure (SBP) (HR, 2.649; 95% CI, 1.133–6.194; p = 0.025) were risk factors for proteinuria. Serum albumin levels and albumin-bilirubin scores in patients with proteinuria worsened. In addition, a mean SBP ≥135 mm Hg during treatment was the only risk factor for the development of severe proteinuria (UPCR >2 g/g Cr). Conclusion: Our study found that controlling blood pressure is extremely important for the management of proteinuria in patients with HCC who are receiving Atezo + Bev. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene

Author

Miura, Ryoichi, primary, Kawaoka, Tomokazu, additional, Imamura, Michio, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Shirane, Yuki, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Kodama, Kenichiro, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Hinoi, Takao, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

23. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment

Author

Yamaoka, Kenji, primary, Kodama, Kenichiro, additional, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Yano, Shigeki, additional, Murakami, Serami, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Uchida, Takuro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Miki, Daiki, additional, Imamura, Michio, additional, Takahashi, Shoichi, additional, Nagao, Akiko, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

24. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Johira, Yusuke, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Fujii, Yasutoshi, additional, Kodama, Kenichiro, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Nonaka, Michihiro, additional, Hyogo, Hideyuki, additional, Aisaka, Yasuyuki, additional, Azakami, Takahiro, additional, Hiramatsu, Akira, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

25. A patient with chronic hepatitis B who developed hepatocellular carcinoma with hypervascularity in 9 years of close follow-up

Author

Kosaka, Masanari, primary, Kawaoka, Tomokazu, additional, Johira, Yusuke, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Andou, Yuuwa, additional, Kosaka, Yumi, additional, Kodama, Kenichiro, additional, Uchikawa, Sinsuke, additional, Fujino, Hatsue, additional, Oono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Kuroda, Shintaro, additional, Kobayashi, Tsuyoshi, additional, Ohdan, Hideki, additional, Nakamura, Yuko, additional, Awai, Kazuo, additional, Kido, Aya, additional, Sentani, Kazuhiro, additional, Oue, Naohide, additional, Arihiro, Koji, additional, and Aikata, Hiroshi, additional

Published
2022
Full Text
View/download PDF

26. Efficacy and Safety of Chemoradiation Therapy Using One- Shot Cisplatin via Hepatic Arterial Infusion for Advanced Hepatocellular Carcinoma with Major Macrovascular Invasion: a Single-arm Retrospective Cohort Study

Author

Naruto, Kensuke, primary, Kawaoka, Tomokazu, additional, Kodama, Kenichiro, additional, Ogawa, Yutaro, additional, Amioka, Kei, additional, Yoshikawa, Yuki, additional, Kikukawa, Chihiro, additional, Suehiro, Yousuke, additional, Yamaoka, Kenji, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Ohno, Atsushi, additional, Uchida, Takuro, additional, Yamauchi, Masami, additional, Okamoto, Wataru, additional, Takahashi, Shoichi, additional, Imamura, Michio, additional, Chosa, Keigo, additional, Awai, Kazuo, additional, Kubo, Katsumaro, additional, Nagata, Yasushi, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

27. Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Author

Johira, Yusuke, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Kodama, Kenichiro, additional, Uchikawa, Shinsuke, additional, Fujino, Hatsue, additional, Ono, Atsushi, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Okamoto, Wataru, additional, Yamauchi, Masami, additional, Imamura, Michio, additional, Sentani, Kazuhiro, additional, Oue, Naohide, additional, Arihiro, Koji, additional, Kuroda, Shintaro, additional, Kobayashi, Tsuyoshi, additional, Ohdan, Hideki, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

28. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

Author

Ando, Yuwa, primary, Kawaoka, Tomokazu, additional, Kosaka, Masanari, additional, Shirane, Yuki, additional, Johira, Yusuke, additional, Miura, Ryoichi, additional, Murakami, Serami, additional, Yano, Shigeki, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Kodama, Kenichiro, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Ono, Atsushi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Okamoto, Wataru, additional, Takahashi, Shoichi, additional, Imamura, Michio, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

29. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma

Author

Naruto, Kensuke, primary, Kawaoka, Tomokazu, additional, Amioka, Kei, additional, Ogawa, Yutaro, additional, Chihiro, Kikukawa, additional, Yoshikawa, Yuki, additional, Ando, Yuwa, additional, Suehiro, Yosuke, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Kodama, Kenichiro, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Murakami, Eisuke, additional, Nakahara, Takashi, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Fukuhara, Takayuki, additional, Takaki, Shintaro, additional, Mori, Nami, additional, Tsuji, Keiji, additional, Nonaka, Michihiro, additional, Hyogo, Hideyuki, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kohno, Hirotaka, additional, Kohno, Hiroshi, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Azakami, Takahiro, additional, Imamura, Michio, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

30. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma

Author

Ando, Yuwa, primary, Kawaoka, Tomokazu, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Ogawa, Yutaro, additional, Yoshikawa, Yuki, additional, Kikukawa, Chihiro, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Fukuhara, Takayuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Nonaka, Michihiro, additional, Hyogo, Hideyuki, additional, Aisaka, Yasuyuki, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Moriya, Takashi, additional, Naeshiro, Noriaki, additional, Takahashi, Shoichi, additional, Imamura, Michio, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

31. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy

Author

Amioka, Kei, primary, Kawaoka, Tomokazu, additional, Ogawa, Yutaro, additional, Kikukawa, Chihiro, additional, Naruto, Kensuke, additional, Yoshikawa, Yuki, additional, Ando, Yuwa, additional, Kosaka, Yumi, additional, Uchikawa, Shinsuke, additional, Morio, Kei, additional, Fujino, Hatsue, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Yamauchi, Masami, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Fukuhara, Takayuki, additional, Mori, Nami, additional, Takaki, Shintaro, additional, Tsuji, Keiji, additional, Masaki, Keiichi, additional, Honda, Yoji, additional, Kouno, Hirotaka, additional, Kohno, Hiroshi, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

32. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein

Author

Kosaka, Yumi, primary, Kimura, Tomoki, additional, Kawaoka, Tomokazu, additional, Ogawa, Yutaro, additional, Amioka, Kei, additional, Naruto, Kensuke, additional, Yoshikawa, Yuki, additional, Kikukawa, Chihiro, additional, Suehiro, Yosuke, additional, Yamaoka, Kenji, additional, Ando, Yuwa, additional, Uchikawa, Shinsuke, additional, Morio, Kei, additional, Nakahara, Takashi, additional, Murakami, Eisuke, additional, Takahashi, Shoichi, additional, Tsuge, Masataka, additional, Hiramatsu, Akira, additional, Imamura, Michio, additional, Chosa, Keigo, additional, Awai, Kazuo, additional, Nagata, Yasushi, additional, Chayama, Kazuaki, additional, and Aikata, Hiroshi, additional

Published
2021
Full Text
View/download PDF

33. Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Author

Johira, Yusuke, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, and Imamura, Michio

Subjects
HEPATOCELLULAR carcinoma, ATEZOLIZUMAB, BEVACIZUMAB, FIBROBLAST growth factor receptors
Abstract

Dynamic computed tomography (CT) showed a hepatic mass, 40 mm in diameter, in the lateral segment of the liver, with strong and homogeneous enhancement in the arterial phase (shown in Fig. CT performed 4 weeks after lenvatinib initiation revealed remarkable tumor shrinkage accompanied by decreased tumor vascularity and viability, suggesting partial response on modified RECIST. CT, computed tomography; EOB-MRI, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging. [Extracted from the article]

Published
2022
Full Text
View/download PDF

34. Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Author

Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Kawaoka T, Miki D, Tsuge M, Hayes CN, and Oka S

Subjects
Humans, Male, Female, Aged, Retrospective Studies, Middle Aged, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Aged, 80 and over, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors administration & dosage, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Immunological administration & dosage, Liver Neoplasms drug therapy, Carcinoma, Hepatocellular drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized administration & dosage, Bevacizumab therapeutic use, Bevacizumab administration & dosage, Bevacizumab adverse effects
Abstract

The efficacy and safety of immune-checkpoint inhibitors (ICI) for the treatment of unresectable hepatocellular carcinoma are known. We explored ICI rechallenges with direct switching from 1 ICI regimen to another. This retrospective study included 16 patients who received atezolizumab-bevacizumab (Atezo+Bev) and durvalumab-tremelimumab (Dur+Tre) as the first-line and second-line combination therapy, respectively, at Hiroshima University Hospital. The radiological response and adverse event were evaluated in all patients. Of the 16 patients, 12 were male, and the median age at Atezo+Bev induction was 71 years. The reasons for medication changes were disease progression in 11 patients and adverse events in 5 patients. With Atezo+Bev and Dur+Tre initiation, the Barcelona-Clinic Liver-Cancer stage (A/B/C) progressed in 9/6/3 and 3/4/9 patients and the Child-Pugh classification (A/B/C) progressed in 12/4/0 and 9/6/3 patients, respectively. The disease control rate and overall response rate of Atezo+Bev were 87.5% and 58.3%, respectively, and of Dur+Tre were 62.5% and 0%, respectively. The most common immune-related adverse event in both the Atezo+Bev and Dur+Tre groups was colitis; 3 of the 5 patients with colitis on Atezo+Bev treatment had colitis with Dur+Tre, and 2 had exacerbations. Regarding liver function, ALBI score significantly decreased during Atezo+Bev, but not Dur+Tre, treatment. In patients with colitis following Atezo+Bev, subsequent Dur+Tre treatment may induce colitis recurrence or exacerbation. For immune-related adverse events other than colitis, Dur+Tre could provide relatively safe disease control while maintaining liver function., Competing Interests: This work was supported by JSPS KAKENHI Grant Number 23K07463, Takeda Science Foundation Grant Number 2022043779, 2022 Bristol-Myers Squibb KK Research Grants and by The Hiroshima University Fund “Nozomi H Foundation” subsidy for the promotion of cancer treatment research.TK received honorarium from Astra Zeneca and Chugai Pharma. The other authors have no conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results